TrialStudy of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia
Trial details
- Registry ID
- NCT03257462
- Phase
- Phase 2
SPRB
Spruce Biosciences
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
7Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceStudy to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
Trial details
- Registry ID
- NCT03687242
- Phase
- Phase 2
A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH
Trial details
- Registry ID
- NCT04457336
- Phase
- Phase 2
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
Trial details
- Registry ID
- NCT04544410
- Phase
- Phase 2
A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH
Trial details
- Registry ID
- NCT05128942
- Phase
- Phase 2
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
Trial details
- Registry ID
- NCT05370521
- Phase
- Phase 2
Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)
Trial details
- Registry ID
- NCT07579910
- Phase
- Phase 3
Latest recorded trial changes
A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH
NCT05128942 · Spruce Biosciences
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Number of participants with Treatment-emergent adverse event (TEAE) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
+ After
Measure: Number of Participants With Treatment-emergent Adverse Event (TEAE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
Actual enrollment increased by 2 participants
− Before
65 participants (actual)
+ After
67 participants (actual)